• Phosphatase Inhibitor Cocktail 3 (100X in DMSO): Protocol an

  2026-06-09

  Phosphatase Inhibitor Cocktail 3 (100X in DMSO) is designed for the preservation of protein phosphorylation states during cell and tissue lysate preparation, crucial for accurate downstream phosphoprotein analyses. It is not suitable for workflows that require the activity of phosphatases, nor for applications incompatible with DMSO or its component inhibitors.

• Ibotenic Acid: NMDA Receptor Agonist in Neurodegenerative Mo

  2026-06-09

  Ibotenic acid empowers precision modeling of neurodegenerative disorders by leveraging its NMDA receptor agonism and robust solubility profile. This article distills protocol insights, highlights troubleshooting strategies, and translates the latest in vivo toxicology findings into actionable advances for neuroscience researchers.

• U-73122: Applied Workflows for Phospholipase C Inhibitor Res

  2026-06-08

  U-73122 empowers researchers to dissect the PLC signaling pathway with precise control over calcium flux and chemotaxis, enabling robust designs for apoptosis and inflammation studies. This article delivers protocol-focused guidance, real-world troubleshooting, and comparative insights, all grounded in recent translational research.

• hiPSC-Derived Intestinal Organoids for CYP2C19 Substrate Stu

  2026-06-08

  This study introduces a streamlined protocol for generating human induced pluripotent stem cell (hiPSC)-derived intestinal organoids, providing a robust in vitro model for pharmacokinetic analysis of orally administered drugs. The work demonstrates enhanced relevance for cytochrome P450 metabolism studies, particularly for evaluating CYP2C19 substrates, and addresses key limitations of traditional models.

• Cefiderocol Activity vs. Resistant Enterobacterales: Insight

  2026-06-07

  The reference study systematically evaluated the in vitro efficacy of cefiderocol against a large European Enterobacterales collection, including strains resistant to meropenem and novel β-lactam/β-lactamase inhibitor combinations. Its findings highlight cefiderocol's superior susceptibility rates, directly informing antimicrobial resistance modeling and antibiotic selection strategies—especially relevant for research on Gram-negative CNS infections.

• Genotyping Kit for Target Alleles: Precision DNA Prep Unveil

  2026-06-06

  Discover how the Genotyping Kit for target alleles of insects, tissues, fishes and cells revolutionizes PCR amplification and single-tube DNA extraction. This article uniquely explores mechanistic precision, assay design, and the latest scientific insights for molecular biology genotyping research.

• L-Alanyl-L-Glutamine: Technical Guide for GI Barrier Researc

  2026-06-05

  L-Alanyl-L-Glutamine (B8228) addresses the challenge of maintaining intestinal barrier integrity and nutrient stability in GI research models. This compound is best utilized where conventional glutamine is unstable or insufficient for antioxidant and mucosal protection workflows. It is not suitable for protocols requiring solubility in DMSO or ethanol.

• Oxaliplatin: Mechanism, Benchmarks, and Preclinical Standard

  2026-06-05

  Oxaliplatin is a platinum-based chemotherapeutic agent that induces apoptosis through DNA adduct formation. It demonstrates potent cytotoxicity in colorectal and other cancers, with established dosing protocols and recognized limits in model reliability. This article synthesizes recent evidence and best practices for integrating Oxaliplatin into cancer research workflows.

• Optimizing Cell Assays with EZ Cap™ Cy5 EGFP mRNA (5-moUTP)

  2026-06-04

  This article addresses persistent challenges in cell viability, proliferation, and cytotoxicity assays, emphasizing how EZ Cap™ Cy5 EGFP mRNA (5-moUTP) (SKU R1011) delivers reproducible, quantitative solutions. Scenario-driven Q&A blocks guide researchers through workflow optimization, data interpretation, and reliable vendor selection, grounded in peer-reviewed evidence and APExBIO’s validated product design.

• Bafilomycin C1: Precision V-ATPase Inhibition in Translation

  2026-06-04

  This thought-leadership article explores the mechanistic impact and strategic application of Bafilomycin C1 as a gold-standard vacuolar H+-ATPases inhibitor in translational research. It integrates biological rationale, experimental best practices, and translational strategy—bridging the latest phenotypic screening innovations with actionable guidance for disease modeling, high-content autophagy assays, and drug discovery pipelines.

• BicD and MAP7 Synergize to Activate Drosophila Kinesin-1

  2026-06-03

  This study dissects how the adaptor protein BicD and microtubule-associated protein MAP7 independently and synergistically activate homodimeric Drosophila kinesin-1 motors, revealing distinct and complementary regulatory mechanisms. These findings reshape our understanding of bidirectional cargo transport and motor protein activation, with practical implications for in vitro reconstitution and recombinant protein research.

• Strategic Innovation in Peptide Synthesis: BOP Reagent in Tr

  2026-06-03

  This article explores the mechanistic and strategic dimensions of BOP reagent in advanced peptide synthesis, bridging its role in phenyl ester preparation with the translational demands of prodrug development for oncology. Leveraging recent advances in triterpene-based chemotherapeutics, we contextualize how robust carboxyl group activation and blocked amino acid derivatives underpin the next generation of targeted drug delivery platforms. Insights are provided for translational researchers seeking to optimize workflow efficiency and clinical relevance in peptide-driven therapeutic innovation.

• Polymyxin B (Sulfate): Precision Tools for CREC Resistance R

  2026-06-02

  Explore the unique capabilities of Polymyxin B sulfate for combating multidrug-resistant Gram-negative infections, including advanced insights into carbapenem-resistant Enterobacter cloacae. This in-depth article highlights assay strategies and resistance dynamics not covered in other resources.

• Tubastatin A Reduces Myocardial Damage Post-Resuscitation vi

  2026-06-02

  A recent porcine study demonstrates that Tubastatin A, a selective HDAC6 inhibitor, significantly alleviates myocardial injury after cardiac arrest and resuscitation. This effect is mechanistically linked to the suppression of GSDME-mediated pyroptosis and MLKL-mediated necroptosis, highlighting new therapeutic strategies for post-resuscitation care.

• Tacrine Hydrochloride Hydrate: Benchmarks in Alzheimer's Res

  2026-06-01

  Tacrine hydrochloride hydrate is a first-generation acetylcholinesterase inhibitor widely used in Alzheimer's disease research for its dual-site inhibition and neuroprotective actions. Its potency, mechanisms, and translational relevance are supported by robust peer-reviewed data and validated experimental protocols.

16983 records 2/1133 page Previous Next 12345 下5页 Last page